Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Therapeutic formulation for reduced drug side effects

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Publication Date:
    February 09, 2021
  • Additional Information
    • Patent Number:
      10912,744
    • Appl. No:
      16/579054
    • Application Filed:
      September 23, 2019
    • Abstract:
      The present invention provides drug therapy formulations for reducing the side effects associated with a therapeutic. In some embodiments, the present invention provides a reduction in sleep- and diet-related side effects associated with a therapeutic.
    • Inventors:
      KemPharm, Inc. (Celebration, FL, US)
    • Assignees:
      KemPharm, Inc. (Celebration, FL, US)
    • Claim:
      1. A pharmaceutical composition consisting of dexamphetamine nanoparticles, wherein the dexamphetamine nanoparticles have a mean diameter of up to 50 nm, and guanfacine.
    • Claim:
      2. The pharmaceutical composition of 1 , wherein the dexamphetamine nanoparticles have a mean diameter of up to 25 nm.
    • Claim:
      3. A pharmaceutical composition consisting of: a. a component formulated for rapid release consisting of dexamphetamine nanoparticles wherein the dexamphetamine nanoparticles have a mean diameter of up to 50 nm; and b. component formulated for delayed release consisting of guanfacine.
    • Claim:
      4. The pharmaceutical composition of 3 , wherein the dexamphetamine nanoparticles have a mean diameter of up 25 nm.
    • Claim:
      5. A pharmaceutical composition consisting of: a. a component formulated for rapid release consisting of amphetamine nanoparticles wherein the amphetamine nanoparticles consist of levoamphetamine and dexamphetamine, and the amphetamine nanoparticles have a mean diameter of up to 50 nm; and b. a component formulated for delayed release consisting of guanfacine.
    • Claim:
      6. The pharmaceutical composition of claim 5 , wherein said amphetamine nanoparticles have a mean diameter of up to 25 nm.
    • Patent References Cited:
      2013/0039960 February 2013 Desai
      2017/0105983 April 2017 Desai











    • Other References:
      USPTO, Advisory Action regarding U.S. Appl. No. 13/656,415 dated Sep. 22, 2015, 3 pages. cited by applicant
      USPTO, Advisory Action regarding U.S. Appl. No. 13/656,415 dated Mar. 28, 2014, 42 pages. cited by applicant
      USPTO, Final Office Action regarding U.S. Appl. No. 13/656,415 dated Jun. 24, 2015, 40 pages. cited by applicant
      USPTO, non-final Office Action regarding U.S. Appl. No. 13/656,415 dated Sep. 5, 2013, 22 pages. cited by applicant
      USPTO, non-final Office Action regarding U.S. Appl. No. 13/656,415 dated Jan. 7, 2015, 27 pages. cited by applicant
      USPTO, Notice of Allowance regarding regarding U.S. Appl. No. 13/656,415 dated Sep. 23, 2016, 7 pages. cited by applicant
      USPTO, Restriction Election Office Action regarding U.S. Appl. No. 13/656,415 dated May 28, 2013, 10 pages. cited by applicant
      USPTO, non-final Office Action regarding U.S. Appl. No. 15/339,453 dated Nov. 6, 2017, 13 pages. cited by applicant
      USPTO, Restriction Election Office Action regarding U.S. Appl. No. 15/339,453 dated Apr. 24, 2017, 9 pages. cited by applicant
      European Patent Office, Communication under Rule 71(3) regarding Application No. 11 772 852.7 dated Jan. 26, 2018, 68 pages. cited by applicant
      USPTO, Final Office Action regarding U.S. Appl. No. 13/656,415 dated Mar. 28, 2014, 42 pages. cited by applicant
      USPTO, Advisory Action regarding U.S. Appl. No. 13/093,662 dated Dec. 8, 2017, 3 pages. cited by applicant
    • Assistant Examiner:
      Simmons, Chris E
    • Primary Examiner:
      Lundgren, Jeffrey S
    • Attorney, Agent or Firm:
      McAndrews, Held & Malloy, Ltd.
    • Accession Number:
      edspgr.10912744